Ones To Watch News
Refine Search
Biotechnology
San Francisco, USA-based biotech start-up Aiolos Bio has today emerged out of stealth, backed by an oversubscribed $245 million Series A investment. 24 October 2023
Biotechnology
Germany’s BioNTech has presented positive Phase I/II on its CAR-T cell therapy candidate BNT211 in advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2023. 24 October 2023
Pharmaceutical
Privately-held French company Orphelia Pharma, which is focused on pediatric and orphan medicines, has filed a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kizfizo, the first oral liquid formulation of temozolomide. 24 October 2023
Biotechnology
Shanghai-based gene therapy company Belief BioMed (BBM) has out-licensed certain rights for the commercialization of its hemophilia candidate, BBM-H901. 23 October 2023
Biotechnology
Swiss pharma giant Roche has entered into a definitive agreement to acquire Telavant Holdings, a Roivant Sciences company. 23 October 2023
Pharmaceutical
Melbourne, Australia-based Dimerix has appointed Dr David Fuller as chief medical officer (CMO), effective immediately. 23 October 2023
Pharmaceutical
Swiss drugmaker Basilea Pharmaceutica has entered into an asset purchase agreement with privately owned US firm Gravitas Therapeutics for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species. 20 October 2023
Pharmaceutical
In September, USA-based Ionis Pharmaceuticals (Nasdaq: IONS) unveiled positive Phase III clinical data for olezarsen, a ligand-conjugated antisense (LICA) designed to inhibit apolipoprotein C-III (apoC-III). 20 October 2023
Biotechnology
Osaka, Japan-based biotech RegCell today announced the appointment of experienced life science exec Michael McCullar, as its new president, chief executive and representative director. 19 October 2023
Biotechnology
Californian advanced therapy company Nkarta moving forward with plans to leverage the potential of natural killer (NK) cell-based treatments outside of oncology. 19 October 2023
Biotechnology
After scientific advisors recommended that the US regulator not approve a new amyotrophic lateral sclerosis (ALS) therapy, developer BrainStorm Cell Therapeutics has opted to withdraw its submission. 19 October 2023
Pharmaceutical
UK-based drugmaker Advanz Pharma continues to strengthen its portfolio of specialty brands. 18 October 2023
Biotechnology
Sino-American biotech BeiGene became the first Chinese-origin pharma company to market a programmed cell death protein 1 (PD1) therapy for oncology indications in various global markets, beginning with the European Union. 18 October 2023
Biotechnology
Shares USA-based clinical-stage biotech Evelo Biosciences plummeted 59% to $1.20 yesterday, as it announced disappointing top-line results from its Phase II clinical study with EDP2939 in moderate psoriasis. 18 October 2023
Pharmaceutical
A firm in Massachusetts, USA, has won approval for a new kind of medicine, a phosphate absorption blocker, which will be used to treat certain people with chronic kidney disease (CKD). 18 October 2023
Biotechnology
US antiviral-focused biotech Assembly Biosciences saw its share price rocket nearly 95% to $1.42, on news of a research collaboration with Gilead Sciences. 17 October 2023
Biotechnology
Spanish genetic medicines company SpliceBio has signed an exclusive collaboration and licensing agreement with Spark Therapeutics, which was acquired by Swiss pharma giant Roche in a $4.8 billion deal in 2020, to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. 17 October 2023
Biotechnology
In what the company said was a big day for Monte Rosa Therapeutics, a clinical-stage biotech company developing novel molecular glue degrader (MGD)-based medicines, the company announced two major milestones. 17 October 2023
Biotechnology
Chicago, USA-based artificial intelligence and antibody specialist SparX Biopharmaceutical is to embark on a new strategic collaboration with Arovella Therapeutics. 17 October 2023
Biotechnology
Seattle, USA-based biotech Omeros Corporation saw its shares plummet as much as 58% to an all-time low of $0.92 yesterday, after it said it will discontinue development of an experimental therapy to treat a type of kidney disease after a late-stage study failure. 17 October 2023
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze